This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Management of discontinuation syndrome

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • management
    • treatment of discontinuation symptoms depends on
      • (i) whether or not further antidepressant medication is warranted and
      • (ii) the severity of the discontinuation symptoms
    • if further antidepressant treatment is warranted
      • then restarting the antidepressant will cause rapid resolution of the symptoms
    • if further antidepressant treatment is not clinically indicated then management depends on the severity of the discontinuation symptoms
      • majority of symptoms are mild and in these cases treatment usually requires only that the patient be reassured about their self-limiting nature
      • if symptoms are of moderate severity then can be treated symptomatically
        • e.g. insomnia may be treated with a short course of a benzodiazepine
      • if severe discontinuation symptoms then the antidepressant can be reinstated, symptoms will usually resolve within 24 h and then the antidepressant can be withdrawn more cautiously
        • always include an appropriate explanation of the symptoms to the patient and follow-up to ensure that the symptoms have resolved
      • if, when attempting to withdraw and stop an antidepressant, severe discontinuation symptoms appear either during or at the end of a taper
        • consider increasing the antidepressant dose back to the lowest dose that prevented their appearance, and then commencing a slower taper
          • some patients may require a very gradual tapers to prevent discontinuation symptoms reappearing

    • specialist advice may suggest a from current SSRI to fluoxetine, the SSRI with the longest half-life in the management of discontinuation symptoms related to an SSRI/venlafaxine
      • some case reports suggest that fluoxetine can suppress discontinuation symptoms associated with other SSRIs
        • if the switch is successful, fluoxetine can usually be stopped after several weeks of treatment without discontinuation symptoms reappearing
        • effectiveness of this strategy appears to reflect the long half-life of fluoxetine (1.9 days) and its active metabolite norfluoxetine, which has a half-life of 7-15 days

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.